Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

COLCOVID
  NCT04328480		 RCTcolchicinestandard of careCOVID 19 hospitalizedsome concern
640/639 inconclusive
  • inconclusive 17 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
Horby
  NCT04381936		 RCTcolchicinestandard of careCOVID 19 hospitalizedsome concern
5610/5730 inconclusive
    Lanzoni
          NCT04355728    		 RCTstem cellsplaceboCOVID 19 hospitalizedsome concern
    		12/12 suggested
    • suggested 86 % decrease in death D28 with a moderate degree of certainty due to some concern in risk of bias
    • suggested 89 % decrease in deaths,deaths (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
    RECOVERY (colchicine)
          NCT04381936    		 RCTcolchicinestandard of careCOVID 19 hospitalizedsome concern
    		5610/5730 inconclusive
    • inconclusive 1 % increase in deaths,death D28 (PE) with a moderate degree of certainty due to some concern in risk of bias
    GRECCO-19
          NCT04326790    		 RCTcolchicinestandard of careCOVID 19 hospitalizedsome concern
    		55/50 suggested
    • suggested 89 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
    Lopes MIF
          RBR-8jyhxh    		 RCTcolchicineplaceboCOVID 19 hospitalizedhigh
    		19/19 inconclusive
      Salehzadeh
              IRCT20200418047126N1      		 RCTcolchicineplaceboCOVID 19 hospitalizedsome concern
      		50/50 inconclusive
        Comparing two groups showed significantly different only in the duration of hospitalized (P<0.05). Although in colchicine group dyspnea was improved more rapid than the placebo group, but it was not meaningful.
        Drake OBSnon-steroidal anti-inflammatory drugscontrolCOVID 19 hospitalizedNA
        		4205/4205 inconclusive
        • inconclusive 5 % decrease in deaths (PE)
        Bruce OBSnon-steroidal anti-inflammatory drugscontrolCOVID 19 hospitalizedNA
        		54/1168 inconclusive
        • inconclusive 11 % decrease in deaths,deaths (time to event analysis only) (PE)
        Sandhu OBScolchicinestandard of careCOVID 19 hospitalizedNA
        		53/144 suggested
        • suggested 64 % decrease in deaths
        • suggested 1.8-fold increase in hospital discharge
        • suggested 60 % decrease in mechanical ventilation
        Malgorzata OBSanti-inflammatory therapiescontrolCOVID 19 hospitalizedcritical
        		130/66 suggested
        • suggested 59 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
        Scarsi OBScolchicinestandard of careCOVID 19 hospitalizedNA
        		122/142 suggested
        • suggested 85 % decrease in deaths,deaths (time to event analysis only)
        Jeong OBSnon-steroidal anti-inflammatory drugscontrolCOVID 19 hospitalizedNA
        		354/1470 safety concern
        • statistically significant 65 % increase in clinical deterioration (PE)
        • statistically significant 87 % increase in cardiovascular or renal events
        Tsiakos
                  NCT04398004        		 NRaclarithromycineazithromycin plus hydroxychloroquineCOVID 19 hospitalizedserious
        		90/90 uncontrolled
        • [uncontrolled] End of treatment (composite endpoint for clinical improvement): 86.7% (78/90)

        COVID-19 mild to moderate meta-analysis

        COL-COVID (Pascual-Figal)
                  NCT04350320        		 RCTcolchicinestandard of careCOVID-19 mild to moderatesome concern
        		52/51 inconclusive
          Rashad (CLARI vs SoC) RCTclarithromycinestandard of careCOVID-19 mild to moderatesome concern
          		99/99 suggested
          • suggested 1.9-fold increase in radiologic improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias

          COVID-19 severe or critically meta-analysis

          COLCHIVID
                      NCT04367168          		 RCTcolchicineplaceboCOVID-19 severe or criticallyNA
          		66/60 inconclusive
          • inconclusive 17 % decrease in death or transfer to ICU (PE)
          Shi
                      NCT04288102          		 RCTstem cellsplaceboCOVID-19 severe or criticallysome concern
          		66/35 inconclusive
            Shu
                          ChiCTR2000031494            		 RCTstem cellsstandard of careCOVID-19 severe or criticallysome concern
            		12/29 suggested
            • inconclusive 73 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
            • suggested 9.3-fold increase in clinical improvement,clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
            • suggested 5.7-fold increase in clinical improvement (7-day) with a moderate degree of certainty due to some concern in risk of bias
            Brunetti OBScolchicinestandard of careCOVID-19 severe or criticallyNA
            		33/33 suggested
            • suggested 80 % decrease in deaths,death D28
            • suggested 2.5-fold increase in clinical improvement (28-day)
            • suggested 4.0-fold increase in hospital discharge

            PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
            Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

             

            - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons